Klothea initiates longevity-focused human trial of klotho therapy
Klothea Bio has begun enrolling a randomized, double-blind, placebo-controlled Phase 1b trial of AKL003, an alpha‑klotho mRNA therapy, at the GARM Clinic in Próspera, Roatán. The 21-participant study will assess safety, tolerability and exploratory geroscience biomarkers — including circulating alpha‑klotho, epigenetic aging clocks, wearable-derived recovery metrics, mitochondrial function and composite functional scores — to detect signals related to biological aging.
Why it mattersPhase 1b AKL003 trial in Próspera requires sponsors to reassess offshore regulatory and liability risk.